Navigation Links
Stem cells make bone marrow cancer resistant to treatment

Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments.

A report on the evidence, published in the Jan. 1 issue of the journal Cancer Research, may explain why the disease is so persistent, the Johns Hopkins scientists say, and pave the way for treatments that overcome the cells drug resistance. Multiple myeloma affects bone marrow and bone tissue.

Cancer stem cells that have distinct biology and drug sensitivity as compared with the bulk of a cancer may explain why multiple myeloma, like many other cancers, so often relapses even after chemotherapy puts patients into remission, says Richard J. Jones, M.D., professor and director of bone marrow transplant at Hopkins Kimmel Cancer Center and one of the scientists who authored the new report.

The existence of cancer stem cells - a topic of some controversy in cancer biology - is seen by some scientists as a useful explanation for the long history of difficulty in overcoming some cancers persistence.

The Hopkins investigators previously had uncovered a rare stem cell in myeloma, accounting for less than one percent of all the cancers cells. Working with cell samples from myeloma patients, the team found that this stem cell originates from immune system B-cells and is capable of giving rise to the malignant bone marrow cells characteristic of the disease.

In the current study, the scientists isolated stem cells from the blood of four patients with multiple myeloma and transplanted them into mice. All of the animals developed hind-limb paralysis and showed signs of cancer in the bone marrow. By contrast, plasma cells that were transplanted from multiple myeloma patients to mice did not engraft. The Hopkins scientists say that recreating the disease in mice provides more evidence that these cells act as cancer stem cells.

The Johns Hopkins scientists also compared the response of these special stem cells with the bulk of multiple myeloma plasma cells, to four different chemotherapy medications commonly used to treat patients with the disease: dexamethasone, lenadilomide, bortezomib and 4-hydroxycyclophosphamide. While all four agents significantly inhibited the growth of the plasma cells, none inhibited the stem cells.

To their surprise, the research team noted that the multiple myeloma stem cells resemble other types of adult stem cells and exhibit similar properties that may make them resistant to chemotherapy. They found that the stem cells contain high levels of enzymes that neutralize toxins, like cancer drugs, and expel them through miniature pumps on their cell surface. The investigators believe that these drug-fighting enzymes and pumps - also plentiful in normal stem cells - may help cancer stem cells resist treatment.

Nature made normal stem cells very hearty for a reason, namely to survive and help repair damaged tissues and organs after injury or illness, says William Matsui, M.D., an assistant professor of oncology at Hopkins and the studys lead investigator. To us, it makes sense that the same processes that protect normal stem cells also exist in cancer stem cells to make them resistant to chemotherapy. We need to develop new ways to target the specific biology of cancer stem cells to prevent the continued production of mature tumor cells and disease relapse.

Standard cancer therapy is like mowing the weed - it gets rid of the disease transiently but the dandelion always grows back. We need to get rid of the root to cure disease, and therefore need a different type of therapy - mowing wont work, says Jones.

Matsui says the work also may make it possible to track the rare myeloma stem cells as a marker of how well a patient is doing during treatment.

Multiple myeloma is the second most common blood cancer and strikes more than 14,000 Americans each year. Close to 11,000 will die from the disease.


Contact: Vanessa Wasta
Johns Hopkins Medical Institutions

Related medicine news :

1. Jefferson scientists find protein helps pancreatic cancer cells evade immune system and spread
2. New insight into factors that drive muscle-building stem cells
3. Forever young: Differentiation blocked in tumor stem cells
4. Some Immature Brain Cells May Promote Tumors
5. Localized Breast Cancer Cells Have Potential to Spread
6. FOXO factor promotes survival of oxygen-deprived cancer cells
7. Cancer stem cells: know thine enemy
8. Microchip Spots Stray Tumor Cells in the Bloodstream
9. Brain Cells More Powerful Than You Think
10. Microchip-based device can detect rare tumor cells in bloodstream
11. St. Jude finds link between cellular defense processes, showing how cancer cells survive
Post Your Comments:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: